Oncolytic Virus Immunotherapy for Melanoma

Current Treatment Options in Oncology

Volumn 16, Issue 3, 2015, Pages

  Dharmadhikari, Neal ^a   Mehnert, Janice M ^a   Kaufman, Howard L ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Adoptive T cell therapy; BRAF inhibitors; Coxsackievirus; Herpesvirus; Immunotherapy; Interleukin 2; Ipilimumab; JX 594; Melanoma; Newcastle disease virus; Oncolytic virus; Programmed death 1 (PD 1); Reovirus; Talimogene laherparepvec; Treatment

Indexed keywords

ALDESLEUKIN; B RAF KINASE INHIBITOR; CARBOPLATIN; CAVATAK; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; HF 10; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; PELAREOREP; PEMBROLIZUMAB; PEXASTIMOGENE DEVACIREPVEC; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACANTHOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTHRALGIA; BIOSAFETY; CANCER IMMUNOTHERAPY; CELL THERAPY; COLITIS; COST EFFECTIVENESS ANALYSIS; CUTANEOUS MELANOMA; DERMATITIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ERYTHEMA; FEVER; HEPATITIS; HUMAN; INFLAMMATION; INJECTION SITE REACTION; INTESTINE INJURY; MELANOMA; METASTATIC MELANOMA; NEURITIS; NEWCASTLE DISEASE VIRUS; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CARCINOMA; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; REGULATORY T LYMPHOCYTE; SIMPLEXVIRUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MELANOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84924956059     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0326-0     Document Type: Review

References (78)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al., editors. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014.
3. Gilchrist B, Eller M, Geller A, Yaar M. Mechanisms of disease: the pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 1999;340(17):1341–8.
4. Saranga-Perry V, Ambe C, Zager J, Kudchadkar R. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014;64(3):171–85.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma, version 1. 2013. NCCN.org. This reviews the current consensus recommendations for the treatment of melanoma.
6. Kaufman HL, Kirkwood JM, Hodi FS, Amatruda T, Bines SD, Clark JI, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98. This reviews current consensus recommendations for immunotherapy in the treatment of melanoma.
7. Ollila DW, Gleisner AL, Hsueh EC. Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. J Surg Oncol. 2011;104(4):420–4.
8. Kroon BB. Surgery for distant metastatic melanoma improved survival. Ann Surg Oncol. 2012;19(8):2426–7.
9. Chua TC, Scolyer RA, Kennedy CW, Yan TD, McCaughan BC, Thompson JF. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol. 2012;19(6):1774–81.
10. Middleton MR, Grob JJ, Aarosnon N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–66.
11. Sato Y, Uhara H, Ashida A, Okuyama R. Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma. J Dermatol. 2013;40(12):1250–1.
12. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.
13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. This is the pivotal phase III clinical trial that demonstrated an improvement in overall survival with a BRAF inhibitor, vemurafenib, for the treatment of BRAF mutated melanoma and led to FDA approval.
14. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.
15. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703. This is the pivotal phase III clinical trial that demonstrated a survival benefit for combination BRAF and MEK inhibition in patients with BRAF mutated melanoma and led to FDA approval.
16. Faure F, Even J, Kourilsky P. Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol. 1998;18(1–2):77–86.
17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
18. McCardle T, Messina J, Sondak V. Completely regressed cutaneous melanocytic lesion revisited. Semin Oncol. 2009;36(6):498–503.
19. Oble D, Loewe R, Yu P, Mihm M. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009;9:3.
20. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014.
21. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16. This trial demonstrated a significant objective response to high-dose IL-2 in patients with metastatic melanoma and supported the FDA approval of IL-2.
22. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11–4. This study provided data on long-term follow-up of patients who achieved a complete response with high-dose IL-2 and demonstrated the potential durability of immunotherapy responses.
23. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman, JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(13):711–23. This trial demonstrated a significant objective response to high-dose IL-2 in patients with metastatic melanoma and supported the FDA approval of IL-2. This trial was the pivotal phase III study that demonstrated a survival benefit for metastatic melanoma patients treated with ipilimumab, the first T cell checkpoint inhibitor to be approved for the treatment of cancer.
24. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7.
25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. This is a large Phase I study that demonstrated the potential therapeutic activity of PD-1 blockade in a variety of cancers, most notably melanoma and non-small cell lung cancer.
26. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. This study provided clinical data supporting an increased therapeutic benefit when two T cell checkpoint inhibitors targeting CTLA-4 and PD-1 are used in combination for the treatment of metastatic melanoma.
27. Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev. 2014;257(1):250–63.
28. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–70.
29. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One. 2011;16(12):e28683.
30. Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, et al. Purified herpes simplex virus thymidine kinase particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. 2002;9(1):87–95.
31. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23(12):1666–70.
32. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol. 1990;10(1):13–30.
33. Kaufman H, Ruby C, Hughes T, Slingluff C. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.
34. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19(10):1913–22. This clinical trial provides evidence that JX-594, a targeted oncolytic poxvirus, has anti-tumor activity in melanoma providing support for future clinical investigation.
35. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6(5):409.
36. Kaufman HL, DeRaffele G, Mitcham J, Moroziewica D, Cohen SM, Hurst-Wicker KS, et al. Targeting the local tumor microenvironment by vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005;115(7):1903–12.
37. Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 2006;17(2):239–44.
38. Varghese S, Rabkin S. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002;9(12):967–78.
39. Hughes T, Coffin R, Lilley C, Ponce R, Kaufman H. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virother. 2014;3:11–9. This is a review article for the treatment of malignant melanoma with T-VEC. In addition to providing preclinical and clinical evidence, it describes the biology of T-VEC and the role of GM-CSF.
40. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
41. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–47.
42. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71. This is a multi-institutional clinical trial demonstrating the therapeutic activity and survival for patients with advanced melanoma treated with oncolytic herpesvirus encoding GM-CSF.
43. Kaufman HL, Bines SD. The OPTiM trial: a phase III prospective randomized clinical trial of an oncolytic herpesvirus encoding GM-CSF in patients with unresectable stage III or IV melanoma. Future Oncol. 2010;6:941–9.
44. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin R, Kim-Schulze S. Local immunity induced by intralesional vaccination with an oncolytic herpesvirus encoding GM-CSF in patients with Stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–30. This study reports the immune response in melanoma patients treated with talimogene laherparepvec and demonstrates an increase in effector CD8+ T cells and a decrease in CD4+ regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment of injected lesions.
45. Andtbacka RHI, Collichio F, Amatruda T, Senzer N, Chesney J, Delman K, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (CS) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31:abstr LBA9008.
46. Kaufman HL, Andtbacka RHI, Collichio F, Amatruda T, Senzer NN, Chesney J, et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) vs subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2014;32(5s):abst 9008a.
47. Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenvironment in patients with recurrent breast cancer. Cancer Gene Ther. 2012;19(4):229–37. This clinical trial injected HF10 into patients with recurrent breast cancer and observed its effects in the tumor microenvironment.
48. Takara Bio Inc. Study of HF10 in patients with refractory head and neck cancer or solid tumors with cutaneous and/or superficial lesions. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. Available at: http://clinicaltrials.gov/ct2/show/NCT01017185 NLM Identifier: NCT01017185. Accessed 8 Aug 2014.
49. Kimata H., Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol. 2006;13(8):1078–84.
50. Watanabe D, Tamada Y, Matsumoto Y, Goshima F, Mori I, Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci. 2008;50(3):185–96.
51. Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for entry. J Virol. 1997;71(6):4736–43.
52. Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 2005;26(6):1471–6.
53. Shafrem DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004;10(1 Pt 1):53–60.
54. Andtbacka RHI, Kaufman HL, Daniels GA, Spitler LE, Lutzky J, Hallmeyer S, et al. CALM study: a phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol. 2013;31 (abstr TPS3128).
55. Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW. Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I-signaling. Cancer Res. 2010;70(12):4912–21.
56. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kotke TJ, et al. Phase II trial of intravenous administration of reolysin (reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol Ther. 2012;20(10):1998–2003.
57. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200–ra116.
58. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2(8):e25961.
59. Amgen. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. Available at: http://clinicaltrials.gov/ct2/show/NCT01740297 NLM Identifier: NCT01740297. Accessed 8 Aug 2014.
60. Puzaonv I, Milhelm M, Andtbacka RHI, Minor D, Hamid O, Li A, et al. Primary analysis of a phase Ib multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2014;32(5s):abstr 9029.
61. Merck. Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475. 2014. Available at: http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-enters-strategic-collaborations-amgen-incyte-and-pfizer-evaluat.
62. Jang S, Atkins M. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther. 2014;95(1):24–31. This review article summarizes the role of immunotherapy in BRAF-mutated melanoma with respect to BRAF and MEK inhibitors.
63. Millington G. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002;417:949–54). Clin Exp Dermatol. 2013;38(2):222–3. This article reviews mutations in the BRAF gene and their impact in human cancers.
64. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–94.
65. Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control. 2013;20(4):289–97.
66. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 257(1):56–71.
67. Weber J. At the bedside: adoptive cell therapy for melanoma-clinical development. J Leukoc Biol. 2014;95(6):875–82. This review article supports the use of adoptive T cell therapy in treating melanoma by providing clinical evidence of its effectiveness.
68. Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kotke TJ, et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 2012;72(18):4753–64.
69. Zhao L, Liu H. Newcastle disease virus: a promising agent for tumour immunotherapy. Clin Exp Pharmacol Physiol. 2012;39(8):725–30.
70. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226. The results of this clinical trial supports the combination of oncolytic viruses and CTLA-4 blockade as a therapeutic strategy and demonstrates the importance of the immune system in mediating tumor rejection with the regimen.
71. Cassel W, Murray D. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother. 1992;9(4):169–71.
72. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(11):2122–32.
73. Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW. Monitoring of human immunological responses to vaccinia virus. Methods Mol Biol. 2004;269:243–66.
74. Andtbacka RHI, Ross M, Delman K, Noyes RD, Zager JS, Hsueh E, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Soc Surg Oncol. abstract. 2014.
75. Vile R, Ando D, Kim D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther. 2002;9(12):1062–7.
76. Evans ME, Jordan CT, Chang SM, Conmrad C, Geberding JL, Kaufman HL, et al. Clinical infection control in gene therapy: a multidisciplinary conference. Infect Control Hosp Epidemiol. 2000;21(10):659–73.
77. Guy J, Ekwueme D. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics. 2011;29(10):863–74.
78. Li Q, Liu G, Zhang X. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine. Curr Pharm Biotechnol. 2012;13(9):1773–85.